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URB597Obsessive–compulsive disorder (OCD) is a common psychiatric disorder characterized by the occurrence of
obsessions and compulsions. Glutamatergic abnormalities have been related to the pathophysiology of OCD.
Cannabinoids inhibit glutamate release in the central nervous system, but the involvement of drugs targeting
the endocannabinoid system has not yet been tested in animal models of repetitive behavior. Thus, the aim of
the present study was to verify the effects of the CB1 receptor agonist WIN55,212-2, the inhibitor of
anandamide uptake AM404 and the anandamide hydrolysis inhibitor URB597, on compulsive-associate
behavior in male C57BL/6J mice submitted to the marble burying test (MBT), an animal model used for anti-
compulsive drug screening. WIN55,212-2 (1 and 3 mg/kg), AM404 (1 and 3 mg/kg) and URB597 (0.1, 0.3 and
1 mg/kg) induced a signiﬁcant decrease in the number of buried marbles compared to controls. Pretreatment
with the CB1 receptor antagonist, AM251, prevented both WIN55,212-2 and URB597 effects. These results
suggest a potential role for drugs acting on the cannabinoid system in modulating compulsive behavior.nandamide; CB1, cannabinoid
rcuitry; FAAH, fatty acid amide
burying test; OCD, obsessive–
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The endocannabinoid system plays an important regulatory
role in several brain functions (Ameri, 1999). Anandamide (AEA)
and 2-arachidonoylglycerol (2-AG), the two best characterized
endocannabinoids, are synthesized “on demand” through cleavage
of membrane phospholipids from post-synaptic neurons and act as
retrograde messengers at central synapses. Cannabinoid receptor
type-1 (CB1) is highly expressed throughout the central nervous
system and modulates both excitatory and inhibitory neurotrans-
mission (Herkenham et al., 1990; Schlicker and Kathmann, 2001).
Activation of these receptors on axon terminals regulates ion channel
activity inhibiting neurotransmitter release (Piomelli, 2003; Wilson
and Nicoll, 2001).
The effects mediated by endocannabinoids are usually limited and
short-lasting due to their fast removal from synaptic cleft by a two-
step process that involves internalization and metabolism by the fatty
acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL)enzymes for AEA and 2-AG, respectively (Elphick and Egertova, 2001;
Giuffrida et al., 2001).
Obsessive–compulsive disorder (OCD) is a common psychiatric
condition characterized by the occurrence of obsessions (persistent
intrusive thoughts) and compulsions (deﬁned as ritualistic repetitive
behaviors) which are generally enacted in an effort to somehow
alleviate intense anxiety caused by obsessions. Although OCD patho-
physiology is not completely understood, the therapeutic effects of
selective serotonin reuptake inhibitors suggest the involvement of
serotonergic pathways [for review see Abramowitz et al., 2009].
However, preclinical and clinical data have also shown that atten-
uation of glutamate-mediated neurotransmission could be helpful in
the treatment of OCD patients (Aboujaoude et al., 2009; Egashira et al.,
2008; Grant et al., 2007) indicating that, in addition to serotonin,
glutamatergic abnormalities could also be involved in the patho-
physiology of OCD [for review see Pittenger et al., 2006; Ting and Feng,
2008].
Marble burying in mice was initially related to anxiety behavior
(Njung'e and Handley, 1991). However, recent evidence suggests that
it engages neural circuits implicated in compulsive-associated
behavior (Thomas et al., 2009). As a consequence, the marble burying
test (MBT) has been proposed as an animal model to investigate
repetitive responses involved in OCD (Korff and Harvey, 2006;
Thomas et al., 2009).
A recent study from our group demonstrated that cannabidiol,
a major non-psychotomimetic component of Cannabis sativa, atten-
uates marble burying behavior. This effect was prevented by pre-
treatment with AM251, a CB1 receptor antagonist (Casarotto et al.,
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nisms (Izzo et al., 2009), it can enhance endocannabinoid-mediated
actions by inhibiting the hydrolysis and reuptake of AEA (Bisogno
et al., 2001). Therefore, the cannabidiol effect on marble burying
behavior could have been mediated by facilitation of CB1 receptor-
mediated neurotransmission, suggesting the involvement of the
endocannabinoid system in this behavior.
The aim of the present study, therefore, was to test the hypothesis
that facilitation of CB1 receptor-mediated neurotransmission would
attenuate marble burying behavior.2. Material and methods
2.1. Animals
The experiments were performed using male C57BL/6J mice
weighing 25–30 g. The animals were housed in groups of 15 mice/
cage under a 12 h light cycle (lights on at 7 am) with free access to
food and water. Procedures were conducted in conformity with the
Brazilian Society of Neuroscience and Behavior guidelines for the
care and use of laboratory animals, which are in compliance with
international laws and policies, andwere approved by the local Ethical
Committee (protocol number: 146/2009). All efforts were made to
minimize animal suffering.2.2. Drugs
The following drugs were used: WIN55,212-2 (a CB1 receptor
agonist, Tocris, USA), AM404 (an inhibitor of AEA uptake, Tocris, USA),
URB597 (a FAAH inhibitor, Calbiochem, USA) and AM251 (a CB1
receptor antagonist, Tocris, USA). All drugs were suspended in 2%
Tween 80 in sterile saline (vehicle), except AM404 and AM251, which
were suspended in 2% Tocrisolve™ 100 (Tocris, SA) in sterile saline
and 10% DMSO in sterile saline, respectively. The drugs were injected
intraperitoneally (ip) in a 10 mL/kg volume.2.3. Apparatus and procedure
2.3.1. Marble burying test (MBT)
The test was performed using a squared box (38×32×28 cm)
with a 5 cm sawdust layer covered ﬂoor. Twenty-ﬁve green clear glass
marbles (1.5 cm diameter) were evenly spaced over the ﬂoor. One
hour before testing the animals were left undisturbed in the
experimental room and pre-exposed for 5 min to the sawdust box
without marbles to avoid novelty seeking behavior during the test.
Thirty minutes after the pre-exposition session the animals received
the ip drug injections. In the test session the mice were placed in the
center of marble containing box where they had been previously
exposed to. Thirty minutes later the animals were taken from the box
and the number of buriedmarbles was counted. The criteria for buried
marbles included only those with at least two-thirds under sawdust
(Njung'e and Handley, 1991).2.3.2. Open ﬁeld test
In order to control for a possible non-speciﬁc drug effect on
locomotor activity that could interfere in the MBT, independent
groups of animals were submitted to the open ﬁeld test. It was
performed in a Plexiglas circular arena (40 cm diameter), with 40 cm
high walls. The animals were placed in the arena center and total
distance traveled and the percent of time spent in central and
peripheral zones were measured during 5 min using ANY-MAZE
software (Stoelting, Illinois, USA).2.4. Experimental design
2.4.1. Experiment 1: effects of WIN55,212-2, a CB1 receptor agonist, in
the MBT
Naive mice were randomly divided into groups receiving ip injec-
tions of vehicle (n=6) or WIN55,212-2 (0.3, 1, 3 mg/kg; n=6/group).
The animals were tested 30 min after drug injection. Independent
groups receiving vehicle or WIN55,212-2 (1 or 3 mg/kg) were tested in
the open ﬁeld (n=5/group) 30 min after drug injection. The drug dose
range was based on previous results from the literature (Haller et al.,
2004; Rutkowska et al., 2006).
2.4.2. Experiment 2: effects of URB597, a selective FAAH inhibitor, in the
MBT
Naive mice were randomly divided into groups receiving ip injec-
tions of vehicle (n=6) or URB597 (0.1, 0.3, 1 mg/kg; n=6–7/group).
The animals were tested 30 min after drug injection. Independent
groups of mice receiving vehicle or URB597 (0.1, 0.3, 1 mg/kg) were
also tested in the open ﬁeld (n=5/group) 30 min after drug injection.
The drug dose range was based on previous results from the literature
(Kathuria et al., 2003; Moreira et al., 2008).
2.4.3. Experiment 3: effects of AM404, an inhibitor of AEA uptake, in the
MBT
Naive mice were randomly divided into groups receiving ip injec-
tions of vehicle (n=6) or AM404 (0.3, 1, 3 mg/kg; n=6/group). The
animals were tested 30 min after drug injection. Independent groups
receiving vehicle or AM404 (1 or 3 mg/kg) were tested in the open
ﬁeld (n=6/group) 30 min after drug injection. The drug dose range
was based on previous results from the literature (Patel and Hillard,
2006).
2.4.4. Experiment 4: effects of AM251 on locomotor activity
Naive mice were randomly divided into groups receiving ip
injections of vehicle or AM251 (1 or 3 mg/kg dose; n=6/group)
and submitted to the open-ﬁeld test 60 min after the drug injection.
AM251 doses were based on the dose range that caused no signiﬁcant
effect in anxiety models (Umathe et al., 2009). Independent groups of
animals also received vehicle or AM251 (3 mg/kg) and were
submitted to the marble-burying test.
2.4.5. Experiment 5: effects of pretreatment with AM251, a CB1 receptor
antagonist, on WIN55,212-2 effects in the MBT
Naivemicewere divided into groups receiving a ﬁrst ip injection of
the CB1 receptor antagonist AM251 (AM; 1 mg/kg) or vehicle (VEH)
followed, 30 min later, by a second ip injection ofWIN55,212-2 (WIN;
1 mg/kg) or vehicle. The groups were: VEH–VEH, AM–VEH, VEH–WIN
and AM–WIN (n=6/group). The animals were tested 30 min after the
last drug injection.
2.4.6. Experiment 6: effects of pretreatment with AM251 on URB597
effects in the MBT
Naivemicewere divided into groups receiving a ﬁrst ip injection of
the CB1 receptor antagonist AM251 (1 mg/kg) or vehicle followed,
30 min later, by a second ip injection of URB597 (URB; 0.3 mg/kg)
or vehicle. The groups were: VEH–VEH, AM–VEH, VEH–URB, and AM–
URB (n=7/group). As in experiment 3, the animals were tested
30 min after the last drug injection.
2.5. Statistical analysis
Experiments 1, 2, 3 and 4 were analyzed by one-way ANOVA,
except MBT for experiment 4, which was submitted to Students' t test.
A two-way ANOVA (factors being the ﬁrst and second injections)
was used to analyze experiments 5 and 6. Post-hoc analysis was
436 F.V. Gomes et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (2011) 434–438performed using the Newman–Keuls test. Pb0.05 was considered
signiﬁcant.
3. Results
3.1. Experiment 1: WIN55,212-2 effects in the MBT
As seen in Fig. 1a, WIN55,212-2 (at 1 and 3 mg/kg dose) reduced
the number of buried marbles in a dose-dependent manner compared
to the control group [F(3,20)=31.72; Newman–Keuls, Pb0.05]. How-
ever, the group treated with a 3 mg/kg dose exhibited a reduced
locomotor activity in the open ﬁeld [F(2,12)=10.91; Pb0.05, Fig. 2a].
The drug did not change exploratory activity of the central or pe-
ripheral areas of the open ﬁeld [percent time in the center: F(2,12)=
0.60; percent time in the periphery F(2,12)=0.84; both PN0.05,
Fig. 2b].
3.2. Experiment 2: URB597 effects in the MBT
URB597 (0.1, 0.3, 1 mg/kg) reduced the number of buried mar-
bles in a dose-dependent manner compared to the control group
[F(3,21)=23.11; Newman–Keuls, Pb0.05, Fig. 1b] without affecting
locomotor behavior [F(3,16)=0.46; PN0.05, Fig. 2c] or exploratory
activity in the open ﬁeld [percent time in the center: F(3,16)=1.80;
percent time in the periphery: F(3,16)=1.40; both PN0.05, Fig. 2d].
3.3. Experiment 3: AM404 effects in the MBT
AM404 (1 and 3 mg/kg) reduced the number of buried marbles
compared to the control group [F(3,20)=3.72; Newman–Keuls,
Pb0.05, Fig. 3a] without affecting locomotor behavior [F(2,15)=
0.19; PN0.05, Fig. 3b] or exploratory activity in the open ﬁeld [percent
time in the center: F(2,15)=0.86; percent time in the periphery:
F(2,15)=0.68; both PN0.05, Fig. 3c].
3.4. Experiment 4: effects of AM251 on locomotor activity
Although the higher dose of AM251 tended to decrease the total
distance traveled in the arena, it failed to reach statistical sig-
niﬁcance [F(2,15)=2.70; P=0.09, Fig. 2e]. The drug did not modify
the central and periphery explorations of the apparatus [percent time
in the center: F(2,15)=0.33; percent time in the periphery: F(2,15)=
0.23; both PN0.05, Fig. 2f]. No drug effect was observed in animalsFig. 1. (a) Effect of systemic (ip) injection of WIN55,212-2 (0, 0.3, 1 or 3 mg/kg, n=6/
group) on marble burying test (MBT). (b) Effect of ip injection of URB597 (0, 0.1, 0.3,
1 mg/kg; n=6–7/group) on MBT. Data represent the mean±SEM of buried marbles.
* Pb0.05 from respective control group.treated with the 3 mg/kg dose of AM251 in the MBT [t(10)=0.38,
PN0.05; data not shown].
3.5. Experiment 5: effects of pretreatment with AM251 on WIN55,212-2
effects in the MBT
Conﬁrming results from experiment 1, WIN55,212-2 (1 mg/kg)
decreased the number of buried marbles. AM251 was able to at-
tenuate WIN55,212-2 effects on marble burying [ﬁrst versus second
drug injection interaction, F(1,20)=5.79, Newman–Keuls, Pb0.05,
Fig. 4a].
3.6. Experiment 6: effects of pretreatment with AM251 on URB597 effects
in the MBT
As seen in experiment 1, URB597 (0.3 mg/kg) injection was able to
decrease the number of buried marbles. This effect was prevented by
pretreatment with AM251 [ﬁrst versus second drug injection
interaction, F(1,24)=5.03, Pb0.05, Newman–Keuls, Pb0.05, Fig. 4b].
4. Discussion
The present study showed that treatment with the CB1 receptor
agonist WIN55,212-2 or the FAAH inhibitor URB597 inhibits marble
burying behavior in a dose-dependent manner. These effects were
prevented by a previous injection of the CB1 receptor antagonist
AM251 at a dose that did not induce any signiﬁcant effect by itself.
Conﬁrming the involvement of the cannabinoid system in this
behavior, the endocannabinoid uptake inhibitor AM404 also de-
creased marble burying.
The MBT was ﬁrst designed as an animal model aimed at detecting
anxiolytic drug effects (Njung'e and Handley, 1991). However, several
pieces of evidence have questioned this proposal. The observation
that, contrary to most anxiety tests based on exploratory behavior,
repeated exposure to marbles does not cause behavioral habituation,
led to the proposal that the MBT, instead of measuring novelty-
induced anxiety, would evaluate a natural, repetitive behavior, that
can become compulsive (Njung'e and Handley, 1991; Thomas et al.,
2009). Another argument favoring the proposal that the MBT reﬂects
compulsive-related behavior is the development of tolerance after
repeated treatment with classical anxiolytic compounds such as
diazepam (Casarotto et al., 2010; Ichimaru et al., 1995).
Our laboratory has recently demonstrated an inhibitory effect of
cannabidiol on marble burying behavior. This effect was probably
mediated by facilitation of CB1 receptor-mediated neurotransmis-
sion, since it was prevented by previous administration of the CB1
receptor antagonist AM251 (Casarotto et al., 2010). The present study
extends these previous ﬁndings showing that CB1 receptor agonist
WIN55,212-2, AM404, a drug that is thought to exert its actions by
increasing the availability of AEA for CB1 receptors by inhibiting their
reuptake (Giuffrida et al., 2001), and URB597, a drug that produces
dose-dependent rapid (b15 min) and persistent (N6 h) inhibition of
brain FAAH activity and a signiﬁcant increase in the brain content of
AEA (Kathuria et al., 2003; Piomelli et al., 2006), are also able to inhibit
marble burying behavior. Together, the results reinforce a possible
involvement of the endocannabinoid system in the modulation of
repetitive behaviors.
Impairment of motor function could be a confounding factor in the
MBT and it has been described after treatment with drugs that act in
an endocannabinoid system (Rodriguez de Fonseca et al., 1998;
Sanudo-Pena et al., 2000; Varvel et al., 2005). Although the higher
dose of WIN55,212-2 (3 mg/kg) reduced locomotor activity in the
open ﬁeld, no effect was found with the lower, but also effective dose
(1 mg/kg) of the drug in the MBT. Moreover, conﬁrming other studies
(Piomelli et al., 2006), no effect on motor function was observed with
drugs that facilitate endocannabinoid effects instead of producing a
Fig. 2. (a) Effect of ip injection ofWIN55,212-2 (0, 1 or 3 mg/kg) on total distance traveled and (b) percent time spent in peripheral and central zones in the open-ﬁeld (n=5/group).
(c) Effect of ip injection of URB597 (0, 0.1, 0.3, or 1 mg/kg) on total distance traveled and (d) percent time spent in peripheral and central zones in the open-ﬁeld (n=5/group).
(e) Effect of ip injection of AM251 (0, 1 or 3 mg/kg) on total distance traveled and (f) percent time spent in peripheral and central zones in the open-ﬁeld (n=6/group). Data
expressed as mean±SEM. * Pb0.05 from respective control group.
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that our results in the MBT cannot be attributed to impairment of
motor function.
Anxiolytic effects have been described after treatment with CB1
receptor agonists and FAAH inhibitors (Kathuria et al., 2003; Patel and
Hillard, 2006). Although these effects could have inﬂuenced the
present results, at the doses used WIN55,212-2, AM404 and URB597
did not change the percentage of time spent in the center or periphery
of the open ﬁeld. Since anxiolytic drugs usually increase exploratory
activity of the former area (Prut and Belzung, 2003), acute anxiolytic
effects seem to not be responsible for our results in the MBT.
So far there has been little evidence pointing to an involvement
of cannabinoids in OCD related behaviors. Results obtained from
a pilot study indicated that a single-dose treatment with Δ9-
tetrahydrocannabinol (Δ9-THC) improved compulsive behavior in
patients with Tourette's Syndrome (Muller-Vahl et al., 2002), a
neuropsychiatric disorder characterized by the presence of multiple
physical (motor) tics commonly associated with OCD (Hounie et al.,
2006; Jankovic, 2001). Additionally, an “add-on” effect of dronabi-
nol, a synthetic form of Δ9-THC, improving OCD treatment has been
observed (Schindler et al., 2008).
The neurotransmitter systems related to marble burying behavior
and OCD are still poorly understood. The inhibitory effects of SSRIs inFig. 3. (a) Effect of systemic (ip) injection of AM404 (0, 0.3, 1 or 3 mg/kg, n=6/group) on
distance traveled and (c) percent time spent in peripheral and central zones in the open-
respective control group.this test and its therapeutic effect in OCD patients suggest the
involvement of serotonergic mechanisms (Casarotto et al., 2010). In
addition, recent evidence suggests that glutamatergic neurotransmis-
sion could also be involved (Egashira et al., 2008; Iijima et al., 2010).
Glutamate is the major neurotransmitter in the cortico-striato-
thalamo-cortical (CSTC) circuitry that has been implicated in the
pathophysiology of OCD [for review see Carlsson, 2000; Pittenger
et al., 2006]. Brain imaging studies of OCD patients have demonstrated
a dysfunction of glutamatergic neurotransmission in CSTC circuitry
and patients with OCD show increased glutamate levels in cerebro-
spinal ﬂuid compared to healthy subjects (Chakrabarty et al., 2005).
Moreover, both preclinical and clinical studies suggest that drugs
that attenuate glutamate neurotransmission such as riluzole and
memantine are helpful in the treatment of OCD patients (Aboujaoude
et al., 2009; Grant et al., 2007) and are effective in the MBT (Egashira
et al., 2008; Iijima et al., 2010). However, there are also contradictory
results regarding the possible role of glutamate in this disorder. For
example, a decrease in anterior cingulate cortex glutamate concen-
tration was found in OCD patients (Arnold et al., 2009) and in
transgenic models an anti-glutamatergic drug exacerbated OCD-
associated behaviors (McGrath et al., 2000). Taken together, these
data suggest that OCD could involve, rather than just a general
increase, disregulation of glutamatergic neurotransmission in speciﬁcmarble burying test (MBT). (b) Effect of ip injection of AM404 (1 or 3 mg/kg) on total
ﬁeld (n=6/group). Data represent the mean±SEM of buried marbles. * Pb0.05 from
Fig. 4. Effect of a ﬁrst ip injection of vehicle (VEH) or AM251 (1 mg/kg) followed by a
second ip injection of VEH, (a) WIN55,212-2 (1 mg/kg) or (b) URB597 (0.3 mg/kg) on
MBT (n=6–7/group). Data represent themean±SEM of buriedmarbles. * Pb0.05 from
respective control group.
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cological agents that enhance endogenous cannabinoid signaling
could be interfering in marble burying behavior by facilitating a CB1
receptor-mediated decrease of glutamate release in neural pathways
involved in OCD, further studies using intra-cerebral drug injections
are needed to elucidate the mechanisms of this effect.
In conclusion, the present results indicated that facilitation of CB1
receptor-mediated neurotransmission inhibits marble burying be-
havior, suggesting the involvement of the endocannabinoid system in
the pathophysiology of OCD. They also suggest that drugs targeting
this system could be effective in the control of compulsive associated
behavior.
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